Abstract
The p38 MAP kinases are a family of serine/threonine protein kinases that play a key role in cellular pathways leading to pro-inflammatory responses. We have developed and implemented a method for rapidly identifying and optimizing potent and selective p38α inhibitors, which is amenable to other targets and target classes. A diverse library of druggable, purified and quantitated molecules was assembled and standardized enzymatic assays were performed in a microfluidic format that provided very accurate and precise inhibition data allowing for development of SAR directly from the primary HTS. All compounds were screened against a collection of more than 60 enzymes (kinases, proteases and phosphatases), allowing for removal of promiscuous and non-selective inhibitors very early in the discovery process. Follow-up enzymological studies included measurement of concentration of compound in buffer, yielding accurate determination of Ki and IC50 values, as well as mechanism of action. In addition, active compounds were screened against less desirable properties such as inhibition of the enzyme activity by aggregation, irreversible binding, and timedependence. Screening of an 88,634-compound library through the above-described process led to the rapid identification of multiple scaffolds ( > 5 active compounds per scaffold) of potential drug leads for p38α that are highly selective against all other enzymes tested, including the three other p38 isoforms. Potency and selectivity data allowed prioritization of the identified scaffolds for optimization. Herein we present results around our 3-thio-1,2,4-triazole lead series of p38α selective inhibitors, including identification, SAR, synthesis, selectivity profile, enzymatic and cellular data in their progression towards drug candidates.
Keywords: serine/threonine protein kinases, drug discovery, anti-cytokine biotherapeutics, sar, high throughput screening, library design, thio- triazole
Current Topics in Medicinal Chemistry
Title: Discovery of Highly Selective Inhibitors of p38α
Volume: 5 Issue: 10
Author(s): Ioana Popa-Burke, Steve Birkos, Leonard Blackwell, Lynn Cheatham, Jennifer Clark, John K. Dickson, Jr., Scott Galasinski, William P. Janzen, Jose Mendoza, Jennifer L. Miller, Robert P. Mohney, Paul M. Steed and C. N. Hodge
Affiliation:
Keywords: serine/threonine protein kinases, drug discovery, anti-cytokine biotherapeutics, sar, high throughput screening, library design, thio- triazole
Abstract: The p38 MAP kinases are a family of serine/threonine protein kinases that play a key role in cellular pathways leading to pro-inflammatory responses. We have developed and implemented a method for rapidly identifying and optimizing potent and selective p38α inhibitors, which is amenable to other targets and target classes. A diverse library of druggable, purified and quantitated molecules was assembled and standardized enzymatic assays were performed in a microfluidic format that provided very accurate and precise inhibition data allowing for development of SAR directly from the primary HTS. All compounds were screened against a collection of more than 60 enzymes (kinases, proteases and phosphatases), allowing for removal of promiscuous and non-selective inhibitors very early in the discovery process. Follow-up enzymological studies included measurement of concentration of compound in buffer, yielding accurate determination of Ki and IC50 values, as well as mechanism of action. In addition, active compounds were screened against less desirable properties such as inhibition of the enzyme activity by aggregation, irreversible binding, and timedependence. Screening of an 88,634-compound library through the above-described process led to the rapid identification of multiple scaffolds ( > 5 active compounds per scaffold) of potential drug leads for p38α that are highly selective against all other enzymes tested, including the three other p38 isoforms. Potency and selectivity data allowed prioritization of the identified scaffolds for optimization. Herein we present results around our 3-thio-1,2,4-triazole lead series of p38α selective inhibitors, including identification, SAR, synthesis, selectivity profile, enzymatic and cellular data in their progression towards drug candidates.
Export Options
About this article
Cite this article as:
Popa-Burke Ioana, Birkos Steve, Blackwell Leonard, Cheatham Lynn, Clark Jennifer, Dickson, Jr. K. John, Galasinski Scott, Janzen P. William, Mendoza Jose, Miller L. Jennifer, Mohney P. Robert, Steed M. Paul and Hodge N. C., Discovery of Highly Selective Inhibitors of p38α, Current Topics in Medicinal Chemistry 2005; 5 (10) . https://dx.doi.org/10.2174/1568026054985867
DOI https://dx.doi.org/10.2174/1568026054985867 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammatory Mechanisms in Atherosclerosis: The Impact of Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Label-Free Mass Spectrometry-Based Plasma Proteomics Identified LY6D, DSC3, CDSN, SERPINB12, and SLURP1 as Novel Protein Biomarkers For Pulmonary Tuberculosis
Current Proteomics Meet Our Editorial Board Member
Protein & Peptide Letters Prolactin Induces IL-2 Associated TRAIL Expression on Natural Killer Cells from Chronic Hepatitis C Patients <i>In vivo</i> and <i>In vitro</i>
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial
Current Enzyme Inhibition Nitric Oxide and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Role of Brain NUCB2/nesfatin-1 in the Stress-induced Modulation of Gastrointestinal Functions
Current Neuropharmacology Therapeutic Properties of Mushrooms in Managing Adverse Effects in the Metabolic Syndrome
Current Topics in Medicinal Chemistry Uterine EMG and Cervical LIF - Promising Technologies in Obstetrics
Current Women`s Health Reviews CD8+ T-cell-mediated Non-cytolytic Suppression of Human Immunodeficiency Viruses
Current Drug Targets - Infectious Disorders Sedation and Analgesia in Pediatric Intensive Care
Current Drug Targets The RNA-Dependent-RNA Polymerase, an Emerging Antiviral Drug Target for the Hendra Virus
Current Drug Targets Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Her2/neu Small Interfering RNA Delivered in Culture by a Streptavidin Nanoparticle
Current Drug Delivery Dendritic Cells in Atherosclerosis
Current Pharmaceutical Design Novel Strategies for Effective Actinic Keratosis Treatment: A Review
Current Cancer Therapy Reviews Reporting and Interpretation of the CYP2C19 Genotyping Test for Clopidogrel Dosing
Current Pharmacogenomics and Personalized Medicine Trends in the Pharmacology of Inflammatory and Allergic Eye Disorders
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Central Nervous System Agents in Medicinal Chemistry NSAID Use and the Risk of Parkinsons Disease
Current Drug Safety